Tumours consisting of a glandular component, either an adenoma or adenocarcinoma, and a carcinoid component are uncommon. These tumours can be differentiated into collision, composite or amphicrine tumours. Most cases reported in the literature were mixed adenocarcinoma-carcinoid tumours. To date, only four cases of mixed adenoma carcinoid tumours have been reported in the literature. This case report describes a unique case of collision adenoma-carcinoid tumour in the colon complicated by carcinoid syndrome in a 45-year-old woman who presented with a one-month history of diarrhoea and weight loss. She developed recurrence of the carcinoid component of the tumour four months after endoscopic resection. We conclude that carcinoid syndrome can occur in an adenoma-carcinoid tumour; however, the prognosis of this condition is uncertain.
Adenoma ; pathology ; Carcinoid Tumor ; pathology ; Colonic Neoplasms ; pathology ; Colonoscopy ; Diarrhea ; etiology ; Female ; Humans ; Malignant Carcinoid Syndrome ; pathology ; Middle Aged ; Weight Loss

No abstract available.
Carcinoid Tumor/etiology/*pathology ; Disease Progression ; Gastrointestinal Neoplasms/etiology/*pathology ; Humans ; Ki-67 Antigen/analysis ; Neoplasm Metastasis ; Predictive Value of Tests

No abstract available.
Carcinoid Tumor/etiology/*pathology/ultrasonography ; Colonoscopy ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Muscles/pathology ; Neoplasm Invasiveness ; Rectal Neoplasms/etiology/*pathology/ultrasonography

BACKGROUND/AIMS: Carcinoid tumors are submucosal tumors with metastatic potential. We tried to determine the clinical course of gastrointestinal (GI) carcinoid tumors and find the factors predicting metastasis. METHODS: We reviewed the clinical records of 81 cases with GI carcinoid tumors. Involved organ, age, sex, symptoms, treatments, and metastatic patterns were reviewed. We evaluated the macroscopic and microscopic parameters to predict the metastatic potential of GI carcinoid tumors. RESULTS: The common sites of GI carcinoids were rectum (71.7%), stomach (13.6%), and duodenum (8.6%). Mean age of the patients was 49 years old with a peak incidence of sixth decade. Male to female ratio was 1.38:1. Most symptoms were usually nonspecific. Fifty five patients (67.9%) received endoscopic treatments while 23 patients (28.4%) received surgical treatment. Patients were followed up for a mean period of 15.6 months. There were 10 cases (12.3%) of metastasis. There were significantly more metastasis in patients with tumor size >10 mm (p<0.001), central depression or ulcer (p=0.009) in macroscopic parameter, and with invasion below submucosa, lymphatic or venous invasion, number of mitosis >2, or Ki-67 labeling index >2 in microscopic parameter (p<0.05). Independent factors predicting metastasis were tumor size and central depression or ulcer in multivariate analysis (p=0.002 and p=0.035, respectively). CONCLUSIONS: Patients with tumor size >10 mm, central depression or ulcer, invasion below submucosa, lymphatic or venous invasion, mitosis >2, and Ki-67 labeling index >2 have higher metastatic potential. Those with risk factors predicting metastasis should be treated and followed carefully.
Adult ; Aged ; Carcinoid Tumor/etiology/*pathology ; Disease Progression ; Female ; Gastrointestinal Neoplasms/etiology/*pathology ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Predictive Value of Tests ; Retrospective Studies

ACTH Syndrome, Ectopic ; etiology ; Adult ; Carcinoid Tumor ; pathology ; secretion ; Cushing Syndrome ; etiology ; Humans ; Male ; Pro-Opiomelanocortin ; genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Thymus Neoplasms ; pathology ; secretion

PURPOSE: Several endoscopic resection therapies have been applied for the treatment of rectal carcinoid tumors. However, there is currently no consensus regarding the optimal strategy. We performed a meta-analysis to compare the efficacy and safety of endoscopic mucosal resection (EMR) or modified EMR (m-EMR) versus endoscopic submucosal dissection (ESD) for the treatment of rectal carcinoid tumors. MATERIALS AND METHODS: PubMed, Web of Science, Medline, Embase and CNKI were searched up to the end of January 2014 in order to identify all studies on the effects of EMR (or m-EMR) and ESD on rectal carcinoid tumors. RESULTS: A total of fourteen studies involving 782 patients were included. The pooled data suggested a significantly higher rate of pathological complete resection among patients treated with ESD or m-EMR than those treated with EMR [odds ratio (OR)=0.42, 95% confidence interval (CI): 0.25-0.71; OR=0.10, 95% CI: 0.03-0.33, respectively], while there was no significant difference between the m-EMR group and ESD group (OR=1.19, 95% CI: 0.49-2.86); The procedure time of ESD was longer than EMR or m-EMR groups [mean differences (MD)=-11.29, 95% CI: -14.19 - -8.38, MD= -10.90, 95% CI: -18.69 - -3.11, respectively], but it was insignificance between the EMR and m-EMR groups. No significant differences were detected among the treatment groups with regard to complications or recurrence. CONCLUSION: The results of this meta-analysis suggest that treatment of rectal carcinoid tumors with ESD or m-EMR is superior to EMR, and the efficacy of m-EMR is equivalence to ESD treatment. However, more well-designed studies are needed to confirm these findings.
Carcinoid Tumor/pathology/*surgery ; Dissection/adverse effects ; Endoscopy, Gastrointestinal/*adverse effects ; Humans ; Intestinal Mucosa/pathology/surgery ; Intestinal Neoplasms/pathology/*surgery ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Postoperative Complications/etiology ; Publication Bias ; Rectal Neoplasms/pathology/*surgery ; Time Factors ; Treatment Outcome ; Tumor Burden